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The aim of this study was to identify hereditary and
acquired risk-factors as they are related to the occur-
rence of stroke in children. We identified 21 children
with stroke. A search of the Factor V Leiden mutation,
the Factor II G20210A variant, and the thermolabile
variant of methylenetetrahydrofolate reductase was
performed in patients and in a control group (n 115).
We identified risk factors of acquired and/or hered-
itary nature for stroke in 19 of 21 children. Eleven
children had three or more risk factors, seven had two
risk factors, and one child had only one risk factor. We
found three carriers (14.3%) of the Factor V Leiden
mutation, two carriers (9.5%) of the Factor II
G20210A variant, eleven (52.4%) thermolabile variant
of methylenetetrahydrofolate reductase heterozygote
carriers, and one (4.8%) homozygotes for this variant.
Frequencies of the Factor V Leiden mutation and
the Factor II variant were higher in patients than in
controls, suggesting that these variants are associated
with an increased risk of stroke in childhood. Homozy-
gosity for the thermolabile variant of methylenetetra-
hydrofolate reductase was equally frequent amongst
patients and controls.
Our study confirms that stroke in children is com-
monly associated with a combination of multiple risk
factors, both genetic and acquired, and that the Factor
V Leiden mutation and the Factor II G20210A variant
are predisposing factors for this situation. © 2003 by
Elsevier Inc. All rights reserved.
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Introduction
Pediatric stroke is more common than previously
thought [1]. Its overall incidence has been estimated to be
2.5 cases in 100,000 per year [2], with 44% to 61% of
ischemic origin [2-4]. Awareness of etiologic factors is
essential because recurrence is significant and disabilities
are frequent, endangering quality of life [1,5,6]. Several
conditions have been associated with stroke, including
cardiac disease, vascular abnormalities, endothelial dam-
age, infectious diseases, collagen tissue disease, and some
inborn errors of metabolism and inherited or acquired
coagulation abnormalities that predispose to thrombotic
complications. Reported prothrombotic abnormalities in-
clude anticardiolipin antibody, lupus anticoagulant, defi-
ciencies of protein C, protein S, antithrombin, and plas-
minogen [1,5-11]. New hypercoagulable states are being
identified as risk factors for ischemic stroke in childhood:
the presence of abnormal activated protein C resistance (or
Factor V Leiden), Factor II G20219A variant, and ther-
molabile variant of methylenetetrahydrofolate reductase
(MTHFR C677T) [8-13]. The knowledge of such abnor-
malities is important to define more rational prophylactic
and therapeutic strategies.
The aim of this study was to identify thrombophilic
conditions that might be related to the development of
stroke in children.
Patients and Methods
This retrospective study included 21 children with ischemic stroke
observed in the last 12 years (1987-1999) at Hospital de Crianc¸as Maria
Pia. Neonatal stroke, as well as patients presenting with transient
symptoms, were excluded from this series. The diagnosis of cerebral
ischemic stroke was confirmed in all patients by computerized tomog-
raphy (CT) and/or magnetic resonance imaging (MRI) scans. Addition-
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ally, magnetic resonance angiography (MRA) was performed in three
patients, standard angiography in four, and one child had MRA and
standard angiography.
Data collected included age at diagnosis, sex, previous medical
history, family history, signs and symptoms presented, radiologic find-
ings, treatment, and outcome.
Baseline investigations performed at the time of diagnosis included
complete blood count, blood sedimentation rate and/or C-reactive pro-
tein, liver-function tests, creatinine, blood urea nitrogen, electrolytes,
total cholesterol, triglycerides, lipoprotein (a) [Lp(a)], VDRL, chest
radiography, electrocardiogram, and echocardiogram. Serologic tests,
immunologic profile, muscle biopsy, skin biopsy for fibroblast charac-
terization, and evaluation of cerebrospinal fluid pyruvate and lactic acid
levels were also performed when indicated to establish a specific
etiology.
The thrombophilia investigation included prothrombin, activated
thromboplastin, thrombin and reptilase times, plasma fibrinogen level,
activity of protein C, protein S, antithrombin III and plasminogen,
normalized activated protein C sensitivity ratio (n-APC-SR), total homo-
cysteine plasma level, lupus anticoagulant, anticardiolipin, and anti-2
glycoprotein1 antibodies.
DNA analysis, for detection of Factor V Leiden mutation, Factor II
G20219A variant, and thermolabile variant of methylenetetrahydrofolate
reductase, was performed both in patients and in a control population
(n115) of Portuguese origin, matched by sex and region of origin to the
patient sample. DNA from controls was obtained from anonymous
Guthrie cards (newborn screening of phenylketonuria) by the Chelex
method. DNA from patients was extracted from peripheral blood by
standard methods. Identification of the Factor V Leiden mutation
(G1691A) [5] and Factor II G20210A variant [6] was performed by
polymerase chain reaction-restriction fragment length polymorphism
(PCR-RFLP) with MnlI and HindIII, respectively. The MTHFR variant
was assessed by PCR-RFLP with HinfI in the control population, and by
sequencing (using the primer 5;TGGGCCCCTCACCTGGATG3;) of
the purified PCR fragments in patients.
Fisher’s exact test was used to compare the frequency of risk
genotypes in patients and in controls. Odds ratios, with a 95% confidence
interval, were estimated as an approximation of relative risk, given the
low frequency of risk factors. A P-value less than 0.05 was considered to
be statistically significant.
Results
Clinical Findings
The main clinical findings of our patients are summa-
rized in Table 1: 67 percent were female. The age range
was two months to 13 years with a mean of 5.3 years. Ten
patients had a prior medical history with conditions
predisposing to stroke. Considering family history, only
one child had a father with myocardial infarction by the
age of 45.
Treatment and Outcome
At the acute stage, treatment was only symptomatic.
Heparin therapy was used in three patients: cases 6 and 7
had a corticosteroid dependent nephrotic syndrome, and
case 8 had a cyanotic cardiac disease. Antiplatelet prophy-
laxis was instituted in eight patients (seven with aspirin
and one with indobufene).
Total recovery was achieved by 11 patients (52.4%).
Persistent motor deficit (hemiparesis in seven patients and
quadriparesis in two), symptomatic epilepsy (five pa-
tients), and cognitive impairment (seven patients) were the
main sequelae observed. Five of the eight patients with
seizures at the onset of stroke later developed epilepsy.
Disabilities were as frequent in our patients (47.6%) as
reported by others [7]. Recurrence of stroke occurred in
five patients (23.8%), a frequency similar to previous
reports [5,11,14].
Risk Factors
Known risk factors for stroke were identified in 19
children (Table 1). Risk factors of a hereditary nature were
identified in 10 patients, whereas acquired risk factors were
found in 18 patients. Eleven patients (52.4%) had three or
more risk factors, seven (33.3%) had two, and one (4.8%)
had only one. In two patients, no risk factors were identified.
All recurrences (cases 3, 8, 13, 16 and 18) occurred in
children with identified risk factors (Table 1); these cases
however had a longer follow-up than those without recur-
rences (10.5 vs 7 years).
Genotype distributions for the Factor V Leiden muta-
tion, Factor II, and MTHFR variants are given in Table 2.
Three of the 21 patients (14.3%) were heterozygous for
Factor V Leiden. Two patients (9.5%) carried the Factor II
G20210A variant. The T/T genotype at position 677 of
MTHFR was present in one case (4.8%). When compared
with controls, the difference in allele frequencies at the
Factor V and Factor II loci was not statistically significant
(P  0.074 and P  0.064, respectively), but exhibited a
trend towards increased frequency of these variants
amongst patients. Odds ratios were 4.63 (95% CI: 0.95-
22.40) and 11.79 (95% CI: 1.02-136.52), suggesting that
carriers of these variants have approximately 5-fold and
twelve-fold higher risks of developing stroke than non-
carriers. Homozygosity for the MTHFR variant is equally
frequent amongst patients and controls.
Discussion
A significant number of patients (90%) in our series had
one or more predisposing conditions for stroke. MRA and/or
standard angiography was performed in just eight patients,
and these studies would have identified additional risk
factors. Only 10% did not have any recognizable risk factor,
which is less than the 20-33% referred in literature
[1,2,5,11,12,15]. This difference probably reflects different
depths of investigation. The most frequent risk factor was the
presence of antiphospholipid antibodies (62%), as reported in
other studies [5,9,12,15]. Increased Lp(a) was found in 29%
of the children, which is also in agreement with recent reports
that consider it as an important risk factor for spontaneous
ischemic stroke in childhood [12,13].
We have provided evidence that both Factor V Leiden
mutation and Factor II G20210A variant have influence as
risk factors for stroke in our pediatric population (relative
risks of 4.63 and 11.79, respectively).
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Table 1. Clinical characteristics of the patients - Summary
Patient Sex
Age at
stroke Presentation
Infarct localization or
vascular
involvement
Risk factors
Acquired Inherited
1 M 5yr 5mo Cerebellar syndrome ( L),
R hemiplegia
Bilateral cerebellar hemispheres
( L), pontomesencephalic
transition
Dissection vertebral artery,
cervical trauma, lupus
anticoagulant
Lp(a) 
30mg/dl
2 M 6yr Cerebellar syndrome ( R),
R hemiplegia, cephalalgia
L pons, R median cerebellar
peduncle, L paramedian
occipital
Dissection basilar artery, anti b2-
glycoprotein I Ab
3 F 17mo L amaurosis, L ptosis, L
hemiplegia
5yr 2mo L hemiplegia
5yr 5mo R hemiplegia, aphasia
6yr Bilateral amaurosis Bilateral cerebral hemispheres,
retina
Sneddon syndrome, anti-
cardiolipin Ab
4 F 12yr Seizures Bilateral parietal  occipital Systemic lupus erythematosus,
anti-b2-glycoprotein I Ab
Lp(a) 
30mg/dl
5 F 12yr 10mo Focal seizures Bilateral frontal  occipital Systemic lupus erythematosus,
anti-b2-glycoprotein 1 Ab, lupus
anticoagulant,
hyperhomocystinemia,
hyperlipidemia
6 F 6yr 7mo Cephalalgia, vomiting,
convergent strabismus
LSS thrombosis Nephrotic syndrome,
hyperlipidemia, anticardiolipin
Ab
7 M 5yr Cephalalgia, vomiting LSS thrombosis, L frontal 
parietal
Nephrotic syndrome,
hyperlipidemia
FV Leiden
8 F 1yr 6mo R hemiplegia, aphasia
1yr 10mo L hemiplegia R temporoparietal Cyanotic cardiac disease, heart
surgery
9 M 4yr L hemiplegia R pons Cyanotic cardiac disease,
anticardiolipin Ab
Lp(a) 
30mg/dl
10 F 5yr L hemiplegia Basal ganglia Heart surgery, endocarditis,
hyperlipidemia, lupus
anticoagulant
11 F 1yr 11mo L hemiplegia Basal ganglia Myocarditis, airways infection
12 F 4yr 6mo Cephalalgia, amaurosis Vertebrobasilar Chronic renal insufficency
hypertension, transitory systemic
hypotension, hyperlipidemia,
lupus anticoagulant
13 F 7yr R hemiplegia, Fanconi’s
anemia,
7yr 1mo L hemiplegia Bilateral cerebral hemispheres Hyperlipidemia, hypertension Moyamoya
syndrome
14 M 6yr R hemiplegia L pons Obesity FV Leiden,
Lp(a) 
30mg/dl
15 M 1.5 mo Status epilepticus, coma Bilateral cerebral hemispheres Meningitis, anticardiolipin Ab FV Leiden,
Protein S
deficiency
16 M 13yr Seizures, coma
13 yr  3 mo Dystonia, tetraparesis R cerebral hemisphere Meningitis, anticardiolipin Ab Lp(a) 
30 mg/dl
17 F 2mo Seizures Bilateral cerebral hemispheres FII variant
Lp(a) 
30mg/dl
18 F 13mo L hemiplegia, seizures R cerebral hemisphere
18mo R hemiplegia, seizures L parieto-occipital Airways infection, anticardiolipin
Ab
FII variant
19 F 18mo R hemiplegia, seizures Bilateral cerebral hemispheres Anticardiolipin Ab
20 F 4yr Seizures R frontoparietal
21 F 4yr R hemiplegia Basal ganglia
Abbreviations:
  Lateral predominance
Ab  Antibody
L  Left
LSS  Longitudinal superior sinus
R  Right
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More importantly, however, stroke emerges as a condi-
tion associated with a combination of multiple risk factors,
both inherited and acquired.
It is noteworthy that stroke recurrence occurred only in
patients with recognizable risk factors, as reported by
other series of patients [5,11,12]. This finding highlights
the importance of their identification in the definition of
prognosis and in the management decisions (treatment and
secondary prophylactic measures).
The treatment of stroke in children has been primarily
directed toward stabilizing systemic factors and managing
underlying causes. No randomized, controlled treatment
trials have been completed in children who suffered
stroke. Many of the treatment approaches have been
adapted from studies in adults, which include antithrom-
botic therapies (heparin, low molecular weight heparins,
aspirin, warfarin, and thrombolytic agents), neuroprotec-
tive agents, and immunosuppressive therapy.
Accumulating experience with antithrombotic and anti-
coagulant treatment in children suggests that these agents
can be used safely, although their efficacy and proper dose
still need to be established. Low molecular weight heparin
is increasingly used as the first choice for acute anticoag-
ulant therapy in children with arterial ischemic stroke
(AIS); its indications include arterial dissection, coagula-
tions disorders, embolism from the heart (usually complex
congenital heart disease), and children with progressive or
additional neurologic deficits not caused by cerebral hem-
orrhage during the initial evaluation of a new cerebral
infarction. Aspirin is frequently used as the treatment of
choice for secondary prevention of AIS in situations of
increased risk of recurrence such as cerebral arterial
stenosis. Currently, most older children with AIS are
placed on aspirin even when no cause is identified because
of the risk of recurrence and minimal side effects. Major
uses of warfarin treatment in children include congenital
or acquired heart disease, severe hypercoagulable states,
arterial dissection, and recurrent AIS or transient ischemic
attacks while on aspirin [11,15]. In our study, none of the
patients treated with heparin and/or aspirin had recurrence,
but the restricted number of the cases limits the conclu-
sion. Large controlled clinical trials are required to estab-
lish the role of antithrombotic and other therapies.
In conclusion, our study confirms that stroke in children
is associated with a combination of predisposing condi-
tions, genetic and acquired, often with the presence of
multiple risk factors.
The most important risk factors identified were an-
tiphospholipid antibodies and increased lipoprotein (a).
The Factor V Leiden mutation and Factor II G20210A
variant seem to be relevant predisposing factors for stroke
in children of our study. Further analysis of these risk
factors in larger series of pediatric patients would contrib-
ute to validate these findings. The fact that recurrence
occurred only in children with identified risk factors
suggests that identification of these factors should be
considered for the management of such cases.
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